Skip to main content
. Author manuscript; available in PMC: 2017 Sep 3.
Published in final edited form as: Lancet. 2016 Jul 22;388(10048):983–993. doi: 10.1016/S0140-6736(16)30826-1

Figure 1. Patient eligibility.

Figure 1

*Expression microarray was done on RNA extracted from the first 159 patients based on date of enrolment. †The 101 corresponding protocol biopsies at 12 months post-transplantion were used to identify the optimal gene set based on CADI score at 12 months. ‡These patients were included in analysis of progression versus non-progression of CADI scores, where progression was defined as an increase in CADI score of at least 2 points. §This cohort was used for independent qPCR validation of the 13 gene set. CADI=Chronic Allograft Damage Index. qPCR=quantitative PCR.